21 results on '"Navarro, Willis H"'
Search Results
2. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results
3. National Marrow Donor Program Session: Donor Issues
4. Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults
5. Methodological and Logistical Considerations to Study Design and Data Collection in Racial/Ethnic Minority Populations Evaluating Outcome Disparity in Hematopoietic Cell Transplantation
6. Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant
7. Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
8. Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT-CTN-0903/AMC-080 and BMT-CTN-0803/AMC-071 Trials
9. Long-Term Outcomes of Patients with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in a Multicenter Expanded Access Program Study
10. A Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
11. Differences in Characteristics of US Hematopoietic Stem Cell Transplantation Centers by Proportion of Racial or Ethnic Minorities
12. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study
13. Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder
14. Outcomes and Risks of Autologous Hematopoietic Stem Cell Transplant for Hematological Malignancies in Patients with HIV Infection
15. 21 - Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder
16. 493 - Outcomes and Risks of Allogeneic Hematopoietic Stem Cell Transplant for Hematological Malignancies in Patients with HIV Infection
17. 164 - Outcomes and Risks of Autologous Hematopoietic Stem Cell Transplant for Hematological Malignancies in Patients with HIV Infection
18. Related PBSC Donors Age >60 Have High Rates of Baseline and Donation-Related Pain and Slow Recovery: First Report from the Related Donor Safety Study (RDSafe)
19. Phase I/II Multicenter Clinical Trial of Lenalidomide Maintenance After Allogeneic Hematopoietic Cell Transplant (alloHCT) in Patients with High Risk (HR) Multiple Myeloma (MM)
20. Young Male Donors Provide the Best Chance of Meeting Requested Cell Dose for PBSC and Bone Marrow Transplantation
21. Results of a Prospective Multi-Center Myeloablative Double-Unit Cord Blood Transplantation Trial in Adult Patients With Acute Leukemia and Myelodysplasia (submitted on behalf of the RCI BMT 05-DCB Protocol Team)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.